| Literature DB >> 36222966 |
Ranjan Verma1, Subodh Kumar1, Piyush Garg1, Yogesh Kumar Verma2.
Abstract
Rise in the incidences of chronic degenerative diseases with aging makes wound care a socio-economic burden and unceasingly necessitates a novel, economical, and efficient wound healing treatment. Platelets have a crucial role in hemostasis and thrombosis by modulating distinct mechanistic phases of wound healing, such as promoting and stabilizing the clot. Platelet-rich plasma (PRP) contains a high concentration of platelets than naïve plasma and has an autologous origin with no immunogenic adverse reactions. As a consequence, PRP has gained significant attention as a therapeutic to augment the healing process. Since the past few decades, a robust volume of research and clinical trials have been performed to exploit extensive role of PRP in wound healing/tissue regeneration. Despite these rigorous studies and their application in diversified medical fields, efficacy of PRP-based therapies is continuously questioned owing to the paucity of large samplesizes, controlled clinical trials, and standard protocols. This review systematically delineates the process of wound healing and involvement of platelets in tissue repair mechanisms. Additionally, emphasis is laid on PRP, its preparation methods, handling, classification,application in wound healing, and PRP as regenerative therapeutics combined with biomaterials and mesenchymal stem cells (MSCs).Entities:
Keywords: Biomaterials; Growth factors; Mesenchymal stem cells; Platelet; Platelet-rich plasma; Wound healing
Year: 2022 PMID: 36222966 PMCID: PMC9555256 DOI: 10.1007/s10561-022-10039-z
Source DB: PubMed Journal: Cell Tissue Bank ISSN: 1389-9333 Impact factor: 1.752
Fig. 1The four phases of wound healing. It starts with hemostasis, where blood loss is prevented by platelet plug and fibrin matrix formation. The inflammation phase ensures the removal of dead cell debris and prevents further infection after neutrophil influx (stimulated by histamine release from the mast cell). Monocytes also get differentiated into macrophages to clear leftover dead cells and neutrophils around the wounded area. In the proliferative phase, various cascade culminates, such as keratinocytes migrate to seal the wound; angiogenesis starts for new blood vessel formation, and fibroblast triggers granulation tissue formation. Finally, fibroblast, blood vessels, MSCs, and myofibroblasts trigger tissue remolding, resulting in complete wound closure
Devices used for PRP preparation (Gentile et al. 2010, 2017, 2020; Alves and Grimalt 2018)
| S. No | Device | Company | Blood Collected | Anti-coagulant | Platelet Activator | Description |
|---|---|---|---|---|---|---|
| 1 | Angel® | Arthrex, Inc. Corporate Naples, Florida, USA | Syringe 40–180 mL | Acid citrate dextrose | 10% (v/v) calcium gluconate | It is a closed technique, using software and programmed centrifugation to isolate PRP with a wide range of platelet concentrations from 3 to 18X compared to naïve plasma |
| 2 | Cascade® or Selphyl® | Musculoskeletal Transplant Foundation, Edison, New Jersey, USA | Tube 9 mL | Sodium citrate | CaCl2 | Pellet of activated PRP is prepared after centrifuging 18 ml of blood (9 ml in each tube) at 1100 g for 10 min |
| 4 | C-Punt® | Biomed Device, Modena MO, Italy | Syringe 60 mL | Sodium citrate | CaCl2 | A volume of 9 ml of PRP was harvested after centrifugation at 1200 rpm for 10 min |
| 5 | i-Stem® Preparation System | i-Stem, Biostems, Co., LTD., Seoul, Korea | Tube 20 mL | Sodium citrate | CaCl2 | After first centrifuging at 3000 rpm for 6 min, 1 ml of PPP and 2 ml of RBCs are removed. Suspension is again centrifuged at 3000 rpm for 3 min to obtain 15 ml of A-PRP |
| 6 | MAG-18® | DTS MG Co., Ltd., Seoul, Korea | Tube 19 mL | Sodium citrate | CaCl2 | The sample is collected and centrifuged twice, firstly at 3000 rpm for 6 min and secondly at 3400 rpm for 2 min to harvest 1.5 mL of PRP |
| 8 | Regenlab® | EnBudron b2, 1052 Le Mont-sur-Lausanne, Swiss | 40 mL | Sodium citrate | Thrombin | Blood is collected in five ATS (autologous thrombin serum) Regen tubes (8 mL each). All tubes are centrifuged at 1500 g for 15 min at room temperature using the universal centrifuge (Regen Lab PRP-Centrig) |
| 9 | PRGF Endoret® | Biotechnology Institute (BTI) | Tube 9 mL | sodium citrate | CaCl2 | Sample is centrifuged at 270 g for 7 min |
Fig. 2Preparation of PRP for treatment
Growth factors regulating wound healing process
| S. No | Growth factor | Origin | Function | Future prospective |
|---|---|---|---|---|
| 1 | Platelet-derived growth factor (PDGF) | Platelets, macrophages, endothelial cells, keratinocytes, and muscle cells | It is the first growth factor that is secreted just after injury and regulates various cellular reactions throughout wound healing | The application of PDGF onsets wound healing. Therefore harnessing the effective use of PDGF in wound care increases its economic uses. The chemotaxis nature of PDGF would also be helpful in treating rare diseases |
| Promotes synthesis of TGF-β and IGF-1 | ||||
| It stimulates collagen synthesis and chemotaxis of macrophages and neutrophils | ||||
| 4. Increases hair growth. (Steed | ||||
| 2 | Epidermal growth factor (EGF) | Mainly secreted by platelets and cells like macrophages, fibroblast,and MSCs | Involved in proliferation, migration, and differentiation of epithelial cells and keratinocytes | The application of EGF in wound enhances proliferation of healthy cells, facilitating wound repair |
| Promotes angiogenesis | ||||
| Stimulates hair cell proliferation and regeneration | ||||
| It also triggers epithelization of burn and granulation of wound. (Kim et al. | ||||
| 3 | Transforming growth factor-β (TGF-β) | Macrophages, T-lymphocytes, and keratinocytes | There are three isoforms of TGF-β; TGF-β1, -β2, -β3, having overlapping but unique function in wound healing | The application of TGF-β stimulates key processes of wound healing such as angiogenesis, fibroblast proliferation, collagen synthesis and thus accelerate wound healing |
| TGF-β1 promotes angiogenesis, | ||||
| TGF-β2 and β3 are linked with scarring and fibrosis. They enhance fibroblast and myofibroblast differentiation, extracellular matrix deposition, wound contraction, and scar formation | ||||
| TGF-β triggers proliferation of undifferentiated MSCs, regulates mitogenesis of endothelial, fibroblast, and osteoblasts | ||||
| Inhibits proliferation (of macrophages and lymphocytes) and metalloproteins activity | ||||
| Regulates synthesis of collagen and secretion of collagenase. (Enoch et al. | ||||
| 4 | Vascular endothelial growth factor (VEGF) | Platelets, keratinocytes, macrophages, and fibroblasts | It has a robust paracrine influence on endothelial cells and also promotes angiogenesis of wounds | The VEGF promotes angiogenesis, which ensures a constant supply of oxygen at the site of injury. For instance, a decrease in the supply of oxygen drastically reduces the healing potential of the wound |
| VEGF is a regulator of processes, such as vasculogenesis, lymphangiogenesis, and vascular permeability. (Werner and Grose | ||||
| 5 | Fibroblast growth factor-2 (FGF-2) | Platelets, macrophages, mesenchymal cells, chondrocytes, and osteoblasts | Involved in re-epithelization, angiogenesis, and granulation tissue formation | Previous reports has suggested that FGF-2 is effective in comorbidity such as diabetic cases in which wound healing processes get slow or decline |
| Indirectly stimulates the release of TGF-α | ||||
| Promotes fibroblast proliferation, collagen accumulation and accelerates granulation tissue formation. (Enoch et al. | ||||
| 6 | Insulin-like growth factor (IGF-1) | Platelets, plasma, epithelial cells, endothelial cells, fibroblasts, osteoblasts, and bone matrix | Mainly involved in inflammatory and proliferative phase of wound healing | Among all, IGF-1 significantly promotes wound healing as well as self-renewal and differentiation of cells. For a constant supply of new cells in a dysfunctional tissues, the role of IGF-1 becomes necessary |
| In combination with other growth factors like PDGF and EGF, it can exert a strong synergistic effect and promotes keratinocyte migration and tissue repair. (Reckenbeil et al. | ||||
| 7 | Hepatocyte growth factor (HGF) | Platelets and mesenchymal cells | Regulates cell growth, mortality, and morphogenesis in epithelial and endothelial cells | There is a direct effect of HGF on liver and kidney. HGF helps in the activation of VEGF and stimulates angiogenesis |
| Directly involved in epithelial repair, granulation tissue formation, and neovascularization | ||||
| In combination with VEGF, it exerts a robust cooperative effect that enhances angiogenesis at the injury site. (Conway et al. | ||||
| 8 | Keratinocyte growth factor-2 (KGF-2), also described as fibroblast growth factor-10 (FGF-10) | Fibroblasts and MSCs | It is involved in remolding phase of wound healing: it induces migration and proliferation of keratinocytes | The fouth phase of wound healing lasts for 61 days to 2 years. In long run, the role of KGF-2 is very significant for proper healing of damage tissues |
| Increases the proliferation of epithelial cells. (Enoch et al. | ||||
| 9 | Transforming growth factor (TNF) | Macrophages, mast cells, and T-lymphocytes | Regulates monocyte migration, fibroblast, proliferation, macrophage activation, and angiogenesis. (Giusti et al. | Transforming growth factor (TNF) activates macrophages which kill the microorganism and drastically reduce further infection |
Fig. 3Mechanistic role of PRP in tissue repair
Fig. 4Meta-analysis of cost effectiveness of PRP therapy